Skip to main navigation Skip to search Skip to main content

Cohort profile: Indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - A prospective longitudinal cohort

  • Lisa M. Jamieson*
  • , Gail Garvey
  • , Joanne Hedges
  • , Cathy Leane
  • , Isaac Hill
  • , Alex Brown
  • , Xiangqun Ju
  • , Sneha Sethi
  • , David Roder
  • , Richard M. Logan
  • , Newell Johnson
  • , Megan Smith
  • , Annika Antonsson
  • , Karen Canfell
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Purpose Our aims are to: (1) estimate prevalence, incidence, clearance and persistence of oral human papillomavirus (HPV) infection among Indigenous Australians; (2) identify risk factors associated with oropharyngeal squamous cell carcinoma (OPSCC)-related HPV types (HPV 16 or 18); (3) develop HPV-related health state valuations and; (4) determine the impact on OPSCC and cervical cancers, and the cost-effectiveness of extending publicly-funded HPV vaccination among Indigenous Australians. Participants Participants were recruited from February 2018 to January 2019. Twelve-month follow-up occurred from March 2019 to March 2020. Participants provided socio-demographic characteristics, health-related behaviours including tobacco and alcohol use and sexual history. Health state preferences in regard to HPV vaccination, knowledge regarding HPV infection, OPSCC and cervical cancer were collected using a two-stage standard gamble approach. Participants provided saliva samples and DNA for microbial genotyping was extracted. Findings to date Of the 910 participants who were positive for β-globin at baseline, 35% had any oral HPV infection. The most prevalent HPV types were 13 or 32 (Heck's disease; 23%). The second most prevalent types were associated with OPSCC (HPV 16 or 18; 3.3%). Of the 645 participants who were positive for β-globin at 12-month follow-up, 43% had any HPV infection. Of these, 33% were HPV types 13 or 32 and 2.5% were HPV 16 or 18. Some 588 participants had β-globin positive oral samples at baseline and 12-month follow-up. The prevalence of any oral HPV infection increased from 34% at baseline to 44% at 12-month follow-up; due to increases in HPV types 13 or 32 (20% at baseline and 34% at 12-month follow-up). Future plans Further funding will be sought to continue follow-up of this cohort, and to include (after a full medical history) a thorough clinical examination of the external head and neck; a complete oral examination and examination of the oropharynx. Blood tests for early stage OPSCC will also be undertaken.

Original languageEnglish
Article numbere046928
JournalBMJ Open
Volume11
Issue number6
DOIs
Publication statusPublished - 3 Jun 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cohort profile: Indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - A prospective longitudinal cohort'. Together they form a unique fingerprint.

Cite this